1. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Issue 2 (February 2016) Authors: Mulenga, Veronica; Musiime, Victor; Kekitiinwa, Adeodata; Cook, Adrian D; Abongomera, George; Kenny, Julia; Chabala, Chisala; Mirembe, Grace; Asiimwe, Alice; Owen-Powell, Ellen; Burger, David; McIlleron, Helen; Klein, Nigel; Chintu, Chifumbe; Thomason, Margaret J; Kityo, Cissy; Walker, A Sarah; G... Journal: Lancet infectious diseases Issue: Volume 16:Issue 2(2016:Feb.) Page Start: 169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). Issue 3 (4th April 2020) Authors: Colomban, Olivier; Tod, Michel; Peron, Julien; Perren, Timothy J; Leary, Alexandra; Cook, Adrian D; Sajous, Christophe; Freyer, Gilles; You, Benoit Journal: JNCI cancer spectrum Issue: Volume 4:Issue 3(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Discordance between the results and conclusions of ICON7 – Authors' reply. Issue 13 (October 2015) Authors: Oza, Amit M; Cook, Adrian D; Kaplan, Richard; Parmar, Mahesh K B; Perren, Timothy J Journal: Lancet oncology Issue: Volume 16:Issue 13(2015) Page Start: e478 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Issue 2 (February 2021) Authors: Morgan, Robert D; McNeish, Iain A; Cook, Adrian D; James, Elizabeth C; Lord, Rosemary; Dark, Graham; Glasspool, Rosalind M; Krell, Jonathan; Parkinson, Christine; Poole, Christopher J; Hall, Marcia; Gallardo-Rincón, Dolores; Lockley, Michelle; Essapen, Sharadah; Summers, Jeff; Anand, Anjana; Zach... Journal: Lancet oncology Issue: Volume 22:Issue 2(2021) Page Start: 277 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Progression-free survival in the ICON8 trial – Authors' reply. Issue 10253 (12th September 2020) Authors: James, Elizabeth C; McNeish, Iain A; Cook, Adrian D; Kaplan, Richard; Clamp, Andrew R Journal: Lancet Issue: Volume 396:Issue 10253(2020) Page Start: 757 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Issue 8 (August 2015) Authors: Oza, Amit M; Cook, Adrian D; Pfisterer, Jacobus; Embleton, Andrew; Ledermann, Jonathan A; Pujade-Lauraine, Eric; Kristensen, Gunnar; Carey, Mark S; Beale, Philip; Cervantes, Andrés; Park-Simon, Tjoung-Won; Rustin, Gordon; Joly, Florence; Mirza, Mansoor R; Plante, Marie; Quinn, Michael; Poveda, An... Journal: Lancet oncology Issue: Volume 16:Issue 8(2015:Aug.) Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Issue 8 (August 2015) Authors: Oza, Amit M; Cook, Adrian D; Pfisterer, Jacobus; Embleton, Andrew; Ledermann, Jonathan A; Pujade-Lauraine, Eric; Kristensen, Gunnar; Carey, Mark S; Beale, Philip; Cervantes, Andrés; Park-Simon, Tjoung-Won; Rustin, Gordon; Joly, Florence; Mirza, Mansoor R; Plante, Marie; Quinn, Michael; Poveda, An... Journal: Lancet oncology Issue: Volume 16:Issue 8(2015:Aug.) Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Issue 10260 (31st October 2020) Authors: Parker, Christopher C; Clarke, Noel W; Cook, Adrian D; Kynaston, Howard G; Petersen, Peter Meidahl; Catton, Charles; Cross, William; Logue, John; Parulekar, Wendy; Payne, Heather; Persad, Rajendra; Pickering, Holly; Saad, Fred; Anderson, Juliette; Bahl, Amit; Bottomley, David; Brasso, Klaus; Chah... Journal: Lancet Issue: Volume 396:Issue 10260(2020) Page Start: 1413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Issue 7 (July 2022) Authors: Clamp, Andrew R; James, Elizabeth C; McNeish, Iain A; Dean, Andrew; Kim, Jae-Won; O'Donnell, Dearbhaile M; Gallardo-Rincon, Dolores; Blagden, Sarah; Brenton, James; Perren, Tim J; Sundar, Sudha; Lord, Rosemary; Dark, Graham; Hall, Marcia; Banerjee, Susana; Glasspool, Rosalind M; Hanna, C Louise; ... Journal: Lancet oncology Issue: Volume 23:Issue 7(2022) Page Start: 919 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Issue 10214 (7th December 2019) Authors: Clamp, Andrew R; James, Elizabeth C; McNeish, Iain A; Dean, Andrew; Kim, Jae-Weon; O'Donnell, Dearbhaile M; Hook, Jane; Coyle, Christopher; Blagden, Sarah; Brenton, James D; Naik, Raj; Perren, Tim; Sundar, Sudha; Cook, Adrian D; Gopalakrishnan, Gosala S; Gabra, Hani; Lord, Rosemary; Dark, Graham;... Journal: Lancet Issue: Volume 394:Issue 10214(2019) Page Start: 2084 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗